Company news

Q32 Bio Inc. (NASDAQ:QTTB) news

Q32 Bio Inc. news releases on 6ix. Latest, Sep 30, 2026: Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia…

Q32 Bio Inc. (NASDAQ:QTTB) news

Press releases & updates

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

Q32 Bio Announces $55 Million Private Placement Financing

Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio Announces $10.5 Million Registered Direct Offering

Q32 Bio Sells Complement Inhibitor ADX-097

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

OXB completes acquisition of remaining stake in US subsidiary

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Homology Medicines Declares Distribution to Common Stockholders

Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Q32 Bio and Homology Medicines Announce Merger Agreement

Homology Medicines Reports Third Quarter 2023 Financial Results

Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights

Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU

Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU

Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting